
    
      The standard treatment in patients with refractory or relapsed Hodgkin lymphoma is salvage
      chemotherapy followed by autologous transplantation for responsive patients. However, the
      standard of salvage chemotherapy remains uncertain. This study is to evaluate the efficacy
      and safety of IGEV regimen in a single-center basis.
    
  